A Study to Evaluate the Safety and Tolerability and Explore the Efficacy of Zonisamide as add-on Therapy in Elderly Patients With Refractory Partial Seizures

NCT01546688 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

41

Enrollment

INDUSTRY

Sponsor class

Conditions

Epilepsy

Interventions

DRUG: Zonisamide at targeted daily doses of 100-500 mg/day
DRUG: Placebo administered to match targeted daily doses of 100-500 mg/day

Sponsor

Eisai Limited